Angel H. Bair

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Thomas E. Hutson, Vladimir Lesovoy, V.P. Stus et al. · The Lancet Oncology · 2013 · 405 citations

Medicine, Oncology, Pharmacology +13

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Brian I. Rini, Bohuslav Melichar, Takeshi Ueda et al. · The Lancet Oncology · 2013 · 232 citations · Full text

Medicine, Oncology, Pharmacology +11

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Brian I. Rini, Joan H. Schiller, John P. Fruehauf et al. · Clinical Cancer Research · 2011 · 179 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

Hope S. Rugo, Alison Stopeck, Anil A. Joy et al. · Journal of Clinical Oncology · 2011 · 106 citations · Full text

Medicine, Oncology, Pharmacology +13

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

Thomas E. Hutson, V.P. Stus, Oleg Lipatov et al. · Clinical Genitourinary Cancer · 2016 · 61 citations

Medicine, Oncology, Pharmacology +13